Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

New Survey Finds Majority Of Adults Don't Understand A Key Of High Blood Pressure
A new survey released shows that 3 out of 4 (75%) adults with high blood pressure are not at all familiar with the role of the renin system(1) -- a key regulator of blood pressure in the body.(2) Yet, about 9 out of 10 adults with high blood pressure (89%) both believe the condition is a cause for concern and want to understand what is going on in their body that is causing it.(1) The Omnibus survey, sponsored by Novartis Pharmaceuticals Corporation, was conducted by Harris Interactive(R) among more than 2,400 US adults ages 18+, more than 700 of whom said they have high blood pressure.(3)
generic viagra online
A-B-C-D-E Spells Fitter Future For Nation's Obese Children
The fitness mantra - Activity, Belief, Confidence, Diet and Exercise.
News of the day
Philips Introduces Three New Products To Improve Performance And Patient Comfort For Hospital And Home Ventilation
Royal Philips Electronics (NYSE: PHG, AEX: PHI) introduced three new respiratory support devices: the Respironics V60 and V200, and Trilogy100 ventilators. These ventilation solutions are intended to support breathing in the intensive care, sub-acute, and home care settings. As a family of products, the three devices are well-suited to address the ventilation care challenges that clinicians face on a daily basis, such as treating respiratory failure from exacerbations of chronic obstructive pulmonary disease (COPD) while avoiding ventilator-associated pneumonia.
Mental Health

ImmunoCellular Therapeutics Announces Filing Of Key Patent Application Relating To Cancer Stem Cell Technology

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced the filing of a provisional U.S. patent application relating to its novel vaccine technology targeting cancer stem cells. The patent application relates to new peptide candidates that may significantly expand the potential target patient population for the company"s cancer stem cell vaccine product candidate, ICT-121. Many cancer therapies are limited by their ability to be used only in patients with certain human leukocyte antigen (HLA) types. Identification of the new peptides for use in IMUC"s vaccine should enable the use of IMUC"s product candidate in patients with many different HLA types. The Company currently has 25 issued or pending patents. "This patent application supports our broad and growing portfolio of intellectual property. ICT-121 is an immunotherapy that targets cancer stem cells - a very exciting approach given the product"s mission of destroying cancer cells at their root as well as its proven ability in preclinical studies to be highly targeted for destroying cancer cells," stated Manish Singh, Ph.D., president and chief executive officer of IMUC. "This product may have applicability to multiple types of cancer, but our first clinical target will be glioblastoma. We anticipate filing an Investigational New Drug (IND) application next quarter to begin a Phase I clinical trial of ICT-121." About ICT-121 ICT-121 is IMUC"s cancer stem cell (CSC) vaccine product candidate that consists of a peptide to stimulate a cytotoxic T-lymphocyte (CTL) response to CD133, which is generally overexpressed on the CSCs. It is designed as an "off-the-shelf" vaccine. IMUC will initially evaluate it in a Phase I clinical study for glioblastoma which the company expects to file an IND for in the third quarter of this year. While glioblastoma will be the initial target for ICT-121, CD133 is also overexpressed in colon cancer, breast cancer, liver cancer, prostate cancer, multiple myeloma and melanoma, providing many potential cancer targets for this CSC vaccine in the future. ImmunoCellular Therapeutics, Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009